Bausch + Lomb (NYSE:BLCO – Get Free Report) and Kewaunee Scientific (NASDAQ:KEQU – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
Earnings & Valuation
This table compares Bausch + Lomb and Kewaunee Scientific”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bausch + Lomb | $5.32 billion | 1.37 | -$360.00 million | ($0.48) | -42.45 |
| Kewaunee Scientific | $277.21 million | 0.35 | $9.62 million | $2.76 | 12.14 |
Institutional and Insider Ownership
11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 14.1% of Kewaunee Scientific shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Bausch + Lomb and Kewaunee Scientific, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bausch + Lomb | 1 | 7 | 6 | 1 | 2.47 |
| Kewaunee Scientific | 0 | 1 | 0 | 0 | 2.00 |
Bausch + Lomb currently has a consensus target price of $20.62, suggesting a potential upside of 1.17%. Given Bausch + Lomb’s stronger consensus rating and higher possible upside, equities analysts clearly believe Bausch + Lomb is more favorable than Kewaunee Scientific.
Risk and Volatility
Bausch + Lomb has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Kewaunee Scientific has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.
Profitability
This table compares Bausch + Lomb and Kewaunee Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bausch + Lomb | -3.21% | 4.14% | 1.93% |
| Kewaunee Scientific | 2.97% | 11.61% | 4.82% |
Summary
Kewaunee Scientific beats Bausch + Lomb on 9 of the 15 factors compared between the two stocks.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
About Kewaunee Scientific
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
